Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although an aggressive phenotype of renal cell carcinoma (RCC) is known to frequently be associated with inflammatory paraneoplastic syndrome including serum C-reactive protein (CRP) elevation, the molecular mechanism underlying this clinical phenomenon as well as what yields the malignant phenotype leading to the progression of RCC has yet to be elucidated. Based on the increased level of inflammatory cytokines such as interleukin-6 in advanced cases of RCC, a cytokine-inducible transcription factor, namely, nuclear factor-kappa B (NF-kappa B), may thus play a role in the progression of RCC. An electrophoretic mobility shift assay (EMSA) was carried out to determine the activity of NF-kappa B. Out of 45 cases of RCC, 15 cases (33%) showed a >200% increase in the NF-kappa B activity in comparison with that seen in normal renal tissue. In locally advanced cases (> or =pT3), 64% (9/14) showed an increased activity whereas it was only observed in 19% (6/31) of localized cases (< or =pT2). All three cases with metastases showed an increased NF-kappa B activity. The NF-kappa B activity determined by EMSA was further confirmed by an immunohistochemical analysis using an antibody recognizing the nuclear localization signal (NLS) in p65 subunit of NF-kappa B. The serum CRP elevation correlated with the increased NF-kappa B activation, and therefore NF-kappa B may be a causative transcription factor of inflammatory paraneoplastic syndrome. A high NF-kappa B activity was associated with an increased expression of both the p65 and p50 subunits of NF-kappa B and a concomitant decreased expression of I kappa B alpha. No functional mutations of the I kappa B alpha gene were detected. The NF-kappa B activity may therefore be a late event in carcinogenesis related to tumor development, thereby representing a possible molecular target in the treatment of RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Cited by
Nuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Gurova, K. V., Hill, J. E., Guo, C., Prokvolit, A., Burdelya, L. G., Samoylova, E., Khodyakova, A. V., Ganapathi, R., Ganapathi, M., Tararova, N. D., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508888102 · Cited by 265
Maier, H. J., Schmidt-Straßburger, U., Huber, M. A., Wiedemann, E. M., Beug, H., & Wirth, T. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.03.003 · Cited by 215
“There may also be an association between NF-jB activation and disease progression in oesophageal and renal cancers [47,48].”
BackgroundDigitoxin as an anticancer agent with selectivity for cancer cells: possible mechanisms involved
López-Lázaro, M. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.8.1043 · Cited by 145
Metadata
- Authors
- Oya, M., Takayanagi, A., Horiguchi, A., Mizuno, R., Ohtsubo, M., Marumo, K., Shimizu, N., & Murai, M.
- Venue
- Carcinogenesis
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-03
- Volume
- 24
- Issue
- 3
- Pages
- 377-384
- ISSN
- 0143-3334 (ISSN-L)
- 1460-2180
- OpenAlex
- W2146130275
- Cited by
- 126
- References
- 1
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.